Professor Michael Barry:

A point I was making earlier was that there is only one drug that actually satisfied the criteria but we reimbursed 12. The drugs group in its decision-making is not just taking into account what we say. It is taking into account lots of other parameters like unmet need, no other available therapies, and so on. That should be reassuring for the committee in the sense that it is not purely down to economics. If it was, we would have reimbursed only one orphan drug this year whereas we have reimbursed 12 so far.